US Dollar vs MXN

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

BBIO BridgeBio Pharma Inc

27.44

-0.17 (-0.62%)

Última actualización: 08:44:23

Retrasado por 15 minutos

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

0000950170-24-018811.txt

BridgeBio Pharma (NASDAQ:BBIO)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Haga Click aquí para más Gráficas BridgeBio Pharma.

BridgeBio Pharma (NASDAQ:BBIO)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024

Haga Click aquí para más Gráficas BridgeBio Pharma.

Noticias sobre BridgeBio Pharma Inc BBIO

BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
Martes 18 de Junio 2024 (2 días hace) • GlobeNewswire Inc.

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Lunes 10 de Junio 2024 (1 semana hace) • GlobeNewswire Inc.

BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
Jueves 6 de Junio 2024 (2 semanas hace) • GlobeNewswire Inc.

Form 8-K - Current report
Jueves 6 de Junio 2024 (2 semanas hace) • Edgar (US Regulatory)

BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia
Martes 4 de Junio 2024 (2 semanas hace) • GlobeNewswire Inc.

BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024
Lunes 3 de Junio 2024 (2 semanas hace) • GlobeNewswire Inc.

Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Miércoles 29 de Mayo 2024 (3 semanas hace) • GlobeNewswire Inc.

BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
Viernes 24 de Mayo 2024 (4 semanas hace) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Viernes 17 de Mayo 2024 (1 mes hace) • Edgar (US Regulatory)

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Miércoles 15 de Mayo 2024 (1 mes hace) • GlobeNewswire Inc.

BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
Martes 14 de Mayo 2024 (1 mes hace) • GlobeNewswire Inc.

BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensiti
Lunes 13 de Mayo 2024 (1 mes hace) • GlobeNewswire Inc.

Más de BridgeBio Pharma Inc Artículos de Noticias

Verizon Communications

Deutsche Telekom (QX)

BNP Paribas (QX)

American Express

Health Care Select Sector

Energy Select Sector SPDR

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones